Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Disparities in MCS Use for STEMI-Related Shock Seen Across the US

Caitlin E. Cox

October 21, 2025

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

L.A. McKeown

December 09, 2022

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

News Opinion CV Team Dispatch

January 2021 News Roundup

L.A. McKeown

January 01, 2021

News Daily News

Unwarranted Stress Testing Before Knee, Hip Surgery Is Declining

Caitlin E. Cox

October 07, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Industry News

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

May 02, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

Washington State Sees Increase in Appropriate PCI After AUC Introduction

L.A. McKeown

June 08, 2015

Advertisement

Disparities in MCS Use for STEMI-Related Shock Seen Across the US

Little Pre- and Postmarket Testing for Most Recalled CV Devices

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

January 2021 News Roundup

Unwarranted Stress Testing Before Knee, Hip Surgery Is Declining

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

TCTMD’s Top 10 Most Popular Stories for July 2019

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Washington State Sees Increase in Appropriate PCI After AUC Introduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content